Clincosm LogoSign in Get a demo

A Multicenter Prospective Study of "High Risk" Molecular Typing in Patients With Adult T Lymphoblastic Lymphoma

Sponsor
Sun Yat-sen University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04320992
Collaborator
(none)
207
Enrollment
1
Location
36
Anticipated Duration (Months)
5.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to determine the indicative value of "high risk" molecular typing in patients with adult T lymphoblastic lymphoma

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    207 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    A Multicenter Prospective Study of "High Risk" Molecular Typing in Patients With Adult T Lymphoblastic Lymphoma
    Anticipated Study Start Date :
    Mar 1, 2020
    Anticipated Primary Completion Date :
    Mar 1, 2023
    Anticipated Study Completion Date :
    Mar 1, 2023

    Arms and Interventions

    Arm Intervention/Treatment
    tested group
    controlled group

    Outcome Measures

    Primary Outcome Measures

    1. progression free survival [3-years]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:

    • biopsy proved T lymphoblastic lymphoma

    • newly diagnosed patients

    Exclusion Criteria:
    • patients with biopsy samples unavailable

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou China 51000

    Sponsors and Collaborators

    • Sun Yat-sen University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Qingqing Cai, Chief physician, Sun Yat-sen University
    ClinicalTrials.gov Identifier:
    NCT04320992
    Other Study ID Numbers:
    • B2020-046
    First Posted:
    Mar 25, 2020
    Last Update Posted:
    Mar 26, 2020
    Last Verified:
    Mar 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Lymphoma
    Precursor Cell Lymphoblastic Leukemia-Lymphoma
    Lymphoma, Non-Hodgkin

    Study Results

    No Results Posted as of Mar 26, 2020